Bio-Rad Laboratories Class A
466 hedge funds and large institutions have $6.42B invested in Bio-Rad Laboratories Class A in 2024 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 169 increasing their positions, 167 reducing their positions, and 69 closing their positions.
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
6% more capital invested
Capital invested by funds: $6.06B → $6.42B (+$353M)
1.15% more ownership
Funds ownership: 78.06% → 79.21% (+1.1%)
1% more repeat investments, than reductions
Existing positions increased: 169 | Existing positions reduced: 167
4% less funds holding
Funds holding: 483 → 466 (-17)
20% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 69
43% less call options, than puts
Call options by funds: $16.7M | Put options by funds: $29.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ninety One (UK)
London,
United Kingdom
|
+$138M |
| 2 |
Select Equity Group
New York
|
+$106M |
| 3 |
EARNEST Partners
Atlanta,
Georgia
|
+$39.9M |
| 4 |
SCA
Southpoint Capital Advisors
New York
|
+$32.9M |
| 5 |
FPA
First Pacific Advisors
El Segundo,
California
|
+$32.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$137M |
| 2 |
Morgan Stanley
New York
|
-$81.5M |
| 3 |
Millennium Management
New York
|
-$65.9M |
| 4 |
SHCM
Sachem Head Capital Management
New York
|
-$50.6M |
| 5 |
Amundi
Paris,
France
|
-$49.4M |
BIO Hedge Fund Activity: Q1 2024 in Review
466 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q1 2024, worth a combined $6.42B — up 5.8% from $6.06B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of BIO and 55 opened new positions — a net loss of 14 holders — while 167 trimmed existing stakes and 169 added.
The largest buyer was Ninety One (UK), opening a new position worth an estimated $138M. The largest seller was AllianceBernstein, cutting an estimated $137M.
- 466 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q1 2024, down from 483 in Q4 2023.
- Funds reported $6.42B of Bio-Rad Laboratories Class A stock for Q1 2024, up 5.8% quarter-over-quarter.
- 55 funds opened new Bio-Rad Laboratories Class A positions in Q1 2024 and 69 closed out, a net change of -14 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q1 2024 was Ninety One (UK), an estimated $138M added.
- The largest Bio-Rad Laboratories Class A seller in Q1 2024 was AllianceBernstein, an estimated $137M sold.
Based on aggregated 13F filings for Q1 2024.